Consequently, MCC950/CRID3‐mediated inhibition of NLRP3 has shown beneficial effects in mice and other preclinical species that have been subjected to disease models, among which models of atherosclerosis, myocardial infarction, colitis, and skin and airway inflammation.47, 116, 120, 121, 122, 123. Here, NLRP3 is linked to atherosclerosis.